These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 9661886)

  • 21. Vav transformation requires activation of multiple GTPases and regulation of gene expression.
    Palmby TR; Abe K; Karnoub AE; Der CJ
    Mol Cancer Res; 2004 Dec; 2(12):702-11. PubMed ID: 15634759
    [TBL] [Abstract][Full Text] [Related]  

  • 22. R-Ras induces malignant, but not morphologic, transformation of NIH3T3 cells.
    Cox AD; Brtva TR; Lowe DG; Der CJ
    Oncogene; 1994 Nov; 9(11):3281-8. PubMed ID: 7936652
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reversible regulation of the transformed phenotype of ornithine decarboxylase- and ras-overexpressing cells by dominant-negative mutants of c-Jun.
    Kielosto M; Nummela P; Katainen R; Leaner V; Birrer MJ; Hölttä E
    Cancer Res; 2004 Jun; 64(11):3772-9. PubMed ID: 15172983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcriptional and translational control of ornithine decarboxylase during Ras transformation.
    Shantz LM
    Biochem J; 2004 Jan; 377(Pt 1):257-64. PubMed ID: 14519103
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of p202, a modulator of apoptosis, during oncogenic transformation of NIH 3T3 cells by activated H-Ras (Q61L) contributes to cell survival.
    Xin H; Geng Y; Pramanik R; Choubey D
    J Cell Biochem; 2003 Jan; 88(1):191-204. PubMed ID: 12461788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A modest reduction in c-myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation.
    Bazarov AV; Adachi S; Li SF; Mateyak MK; Wei S; Sedivy JM
    Cancer Res; 2001 Feb; 61(3):1178-86. PubMed ID: 11221849
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombopoietin-mediated sustained activation of extracellular signal-regulated kinase in UT7-Mpl cells requires both Ras-Raf-1- and Rap1-B-Raf-dependent pathways.
    Garcia J; de Gunzburg J; Eychène A; Gisselbrecht S; Porteu F
    Mol Cell Biol; 2001 Apr; 21(8):2659-70. PubMed ID: 11283246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ras transformation of RIE-1 cells activates cap-independent translation of ornithine decarboxylase: regulation by the Raf/MEK/ERK and phosphatidylinositol 3-kinase pathways.
    Origanti S; Shantz LM
    Cancer Res; 2007 May; 67(10):4834-42. PubMed ID: 17510413
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Selective activation of Ha-ras(val12) oncogene increases susceptibilityof NIH/3T3 cells to TNF-alpha.
    Chang MY; Won SJ; Yang BC; Jan MS; Liu HS
    Exp Cell Res; 1999 May; 248(2):589-98. PubMed ID: 10222151
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of overexpression of ornithine decarboxylase (ODC) on growth control and oncogene-induced cell transformation.
    Hibshoosh H; Johnson M; Weinstein IB
    Oncogene; 1991 May; 6(5):739-43. PubMed ID: 1711188
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Modulation of phospholipase D by Ras proteins mediated by its effectors Ral-GDS, PI3K and Raf-1.
    Lucas L; Penalva V; Ramírez de Molina A; Del Peso L; Lacal JC
    Int J Oncol; 2002 Sep; 21(3):477-85. PubMed ID: 12168089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein kinase C-epsilon associates with the Raf-1 kinase and induces the production of growth factors that stimulate Raf-1 activity.
    Ueffing M; Lovrić J; Philipp A; Mischak H; Kolch W
    Oncogene; 1997 Dec; 15(24):2921-7. PubMed ID: 9416835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A role for protein kinase C-delta in the regulation of ornithine decarboxylase expression by oxidative stress.
    Otieno MA; Kensler TW
    Cancer Res; 2000 Aug; 60(16):4391-6. PubMed ID: 10969783
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autocrine activation of an osteopontin-CD44-Rac pathway enhances invasion and transformation by H-RasV12.
    Teramoto H; Castellone MD; Malek RL; Letwin N; Frank B; Gutkind JS; Lee NH
    Oncogene; 2005 Jan; 24(3):489-501. PubMed ID: 15516973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Possible involvement of the inactivation of the Rho-Rho-kinase pathway in oncogenic Ras-induced transformation.
    Izawa I; Amano M; Chihara K; Yamamoto T; Kaibuchi K
    Oncogene; 1998 Dec; 17(22):2863-71. PubMed ID: 9879992
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ornithine decarboxylase regulates the activity and localization of rhoA via polyamination.
    Mäkitie LT; Kanerva K; Andersson LC
    Exp Cell Res; 2009 Apr; 315(6):1008-14. PubMed ID: 19331812
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transformation suppressor activity of C3G is independent of its CDC25-homology domain.
    Guerrero C; Fernandez-Medarde A; Rojas JM; Font de Mora J; Esteban LM; Santos E
    Oncogene; 1998 Feb; 16(5):613-24. PubMed ID: 9482107
    [TBL] [Abstract][Full Text] [Related]  

  • 38. G2A is an oncogenic G protein-coupled receptor.
    Zohn IE; Klinger M; Karp X; Kirk H; Symons M; Chrzanowska-Wodnicka M; Der CJ; Kay RJ
    Oncogene; 2000 Aug; 19(34):3866-77. PubMed ID: 10951580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anti-tumor activity of antizyme which targets the ornithine decarboxylase (ODC) required for cell growth and transformation.
    Iwata S; Sato Y; Asada M; Takagi M; Tsujimoto A; Inaba T; Yamada T; Sakamoto S; Yata J; Shimogori T; Igarashi K; Mizutani S
    Oncogene; 1999 Jan; 18(1):165-72. PubMed ID: 9926931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Raf revertant cells resist transformation by non-nuclear oncogenes and are deficient in the induction of early response genes by TPA and serum.
    Kolch W; Heidecker G; Troppmair J; Yanagihara K; Bassin RH; Rapp UR
    Oncogene; 1993 Feb; 8(2):361-70. PubMed ID: 8426742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.